Start-up mitral valve regurgitation treatment firm 4C Medical Technologies is preparing for the first early feasibility study of an implantable device to be conducted in Japan, company President and CEO Bob Thatcher said March 5 at the Cardiovascular Research Technologies (CRT) annual conference in Washington, DC.
A long-running collaboration between US FDA and the Japanese Pharmaceutical and Medical Device Agency (PMDA) known as Harmonization by...